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Accepted 12 March 2014; Published online 29 April 2014AbstractObjective: This study aimed to identify those comorbidities with greatest impact on patient-reported health status in patients with
chronic obstructive pulmonary disease (COPD) and to develop a comorbidity index that reflects their combined impact.
Study Design and Setting: We included 408 Swiss and Dutch primary care patients with COPD from the International Collaborative
Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts (ICE COLD ERIC) in this cross-sectional analysis. Primary
outcome was the Feeling Thermometer, a patient-reported health status instrument. We assessed the impact of comorbidities at five cohort
assessment times using multiple linear regression adjusted for FEV1, retaining comorbidities with associations P  0.1. We developed an
index that reflects strength of association of comorbidities with health status.
Results: Depression (prevalence: 13.0%; regression coefficient: 9.00; 95% CI: 13.52, 4.48), anxiety (prevalence: 11.8%; regres-
sion coefficient: 5.53; 95% CI 10.25, 0.81), peripheral artery disease (prevalence: 6.4%; regression coefficient: 5.02; 95%
CI10.64, 0.60), cerebrovascular disease (prevalence: 8.8%; regression coefficient: 4.57; 95% CI 9.43, 0.29), and symptomatic heart
disease (prevalence: 20.3%; regression coefficient: 3.81; 95% CI 7.23, 0.39) were most strongly associated with the Feeling Ther-
mometer. These five comorbidities, weighted, compose the COMorbidities in Chronic Obstructive Lung Disease (COMCOLD) index.
Conclusion: The COMCOLD index reflects the combined impact of five important comorbidities from patients’ perspective and com-
plements existing comorbidity indices that predict death. It may help clinicians focus on comorbidities affecting patients’ health status the
most.  2014 The Authors. Published by Elsevier Inc. All rights reserved.
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In patients with chronic obstructive pulmonary disease
(COPD), comorbidities are highly prevalent. Prevalence of
at least one comorbidity inCOPDpopulations is often reported
to be more than 50%, depending on the definition of a comor-
bidity (eg, inclusion of risk factors or focus on clinically man-
ifest diseases), methodology of assessment (eg, patient or
physician reported or assessed through additional tests), and
the source population (eg, primary care patients, those hospi-
talized after acute exacerbation or population-based patient
samples) [1e3]. There are several explanations for why co-
morbidities are so prevalent in patients with COPD, such asAll rights reserved.
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Key findings
 Among common comorbidities, depression, anxi-
ety, peripheral artery disease, cerebrovascular dis-
ease, and symptomatic heart disease have the
largest impact on patient-reported health status in
patients with chronic obstructive pulmonary dis-
ease (COPD) independent of FEV1.
 This combination of comorbidities is different
from comorbidities included in existing comorbid-
ity indices like the Charlson index that predict
mortality. This suggests that the outcome of inter-
est should be defined carefully when selecting a
specific comorbidity index.
What this adds to what is known?
 Although there are several comorbidity indices
available for patients with COPD that were devel-
oped to predict mortality, no comorbidity index ex-
ists that quantifies the combined impact of
comorbidities on patient-reported health status.
What is the implication, what should change now?
 Researchers and clinicians should carefully
consider the outcome an index predicts.
 The COMorbidities in Chronic Obstructive Lung
Disease index presented here may help clinicians
to focus on comorbidities with greatest impact
from the patients’ perspective, and complements
existing comorbidity indices predicting death. Re-
searchers may use the index to efficiently adjust
for confounding by comorbidities or to assess
modification of effects of COPD treatments.older age, physical inactivity or shared risk factors (eg,
smoking or systemic inflammation) [4].
Attempts have been made to measure the relevance of
multi-morbidity. Metrics for multi-morbidity include sim-
ple counts (ie, the sum of separate comorbidities) or indices
where the relative severity of different comorbidities is
considered [5,6]. Examples include the Charlson index
[7], the Cumulative Illness Rating Scale [8], the Index of
Coexisting Disease [9], and the Kaplan index [10]. These
indices are, however, of limited use for patients with COPD
because they were developed in mixed patient populations
[8] or index diseases other than COPD [7,9,10]. Further-
more, for commonly used indices, often only mortality
was considered to weigh the relative severity of the diseases
[7]. Mortality was also the outcome of the recently devel-
oped COPD specific comorbidity test (COTE index), whichidentified 12 comorbidities that predicted mortality in pa-
tients with COPD [11].
Like mortality, patient-reported health status and health-
related quality of life (HRQL) are important measures for
patients with COPD, which are frequently used as out-
comes in clinical research. We use health status as a
patient-reported global measure to express the impact of
physical and mental morbidity on self-perceived health.
There are data to suggest that health status and HRQL
are related but distinct constructs [12]. Although some
studies looked at the impact of single or multiple comorbid-
ities on HRQL [13e17], to our knowledge no comorbidity
index exists that quantifies the combined impact of comor-
bidities on HRQL or patient-reported health status. Such an
index could inform clinicians about comorbidities that
deserve particular attention to increase quality of treatment.
Researchers could use an index summarizing the impact of
comorbidities to assess their combined impact on treatment
effects, in particular if health status or HRQL is the
outcome. The aim of this study was to identify those co-
morbidities with the greatest impact on patient-reported
health status in patients with COPD and to develop a COPD
comorbidity index, the COMorbidities in Chronic Obstruc-
tive Lung Disease (COMCOLD) index that reflects their
combined impact and that enables researchers and clini-
cians to discriminate between patients.2. Methods
2.1. Study design
We conducted a cross-sectional analysis nested within
the prospective the International Collaborative Effort on
Chronic Obstructive Lung Disease: Exacerbation Risk In-
dex Cohorts (ICE COLD ERIC) cohorts. ICE COLD ERIC
is an international multi-site prospective cohort study with
primary care patients with COPD from Switzerland and the
Netherlands. All included patients have provided written
informed consent. The study has been approved of by all
local ethics committees and is registered on www.
ClinicalTrials.gov (NCT00706602). Detailed information
on the study design [18] and the baseline results [19] were
published elsewhere.
2.2. Study population
All patients included in the ICE COLD ERIC cohort
were eligible for this analysis. All patients were
40 years of age, had Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stages 2 to 4 and were
free of exacerbation for at least 4 weeks at baseline. Exclu-
sion criteria were an expected life expectancy of
12 months (assessed by physician), dementia, psychosis,
or other psychiatric morbidity that would invalidate assess-
ment of patient-reported parameters and inability to com-
plete the baseline assessment due to language difficulties.
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2009 (baseline assessment) [18], and follow-up assessments
took place every 6 months. If not stated otherwise, the an-
alyses are based on the baseline assessment data.
2.3. Primary outcome for patient-reported health status
The Feeling Thermometer (FT), a patient-reported
health status instrument, was the primary outcome. The
FT is a modified visual analogue scale presented in the
form of a thermometer with 100 marked intervals (05 dead,
100 5 perfect health) that has been validated in patients
with COPD [20,21]. The FT is also part of the extensively
used and validated EQ-5D developed by the EuroQol group
[22]. We chose the FT as the primary outcome to use a
generic health status instrument to capture the potential in-
fluence of any comorbidity on health status as opposed to a
COPD-specific HRQL instrument like the Chronic Respira-
tory Questionnaire (CRQ) [23] that is likely to be insensi-
tive to effects of some comorbidities.
2.4. Ascertainment and classification of comorbidities
The assessment of the comorbidities was done by expe-
rienced and well-trained study nurses or physicians during
the baseline visits of the cohort study, which took place at
the primary care practices. The patients were asked which
comorbidities they had using open-ended questions. The
patients also brought a list with all drugs they were taking
to the baseline interview. The study nurses or physicians
compared the patient-reported comorbidities with the list
of medications (and in Switzerland also with the patient re-
cords) and clarified with the general practitioners any un-
certainties or mismatches between the patients’ reports,
the drug list, or the patients’ obvious heath condition. We
defined comorbidities based on criteria used in prior litera-
ture [24,25]. Obesity was defined as body mass index
(BMI) 30 kg/m2, serum creatinine measurements were
used to calculate glomerular filtration rates (GFRs), and
chronic kidney disease was defined by self-report as well
as GFR of !60 mL/min using an accepted equation [26].
Diagnoses of coronary heart disease and heart failure were
considered as symptomatic heart disease, and diagnoses ce-
rebrovascular accident and transient ischemic attack as ce-
rebrovascular disease. To identify patients with anxiety and
depression, we also used the scores from the Hospital Anx-
iety and Depression Scale [27] and defined patients as hav-
ing anxiety or depression if their score was 11 points or
higher [28].
2.5. A priori criteria of the COMCOLD index
We defined the following a priori criteria for the COM-
COLD index: (1) we did not consider asthma as a comor-
bidity because the symptoms can be very similar to those
of COPD; (2) the higher the index the greater the impact
of comorbidities on health status of patients with COPD,independent from COPD severity; (3) the index should be
interpretable in terms of its impact on patient-reported
health status. Therefore, we determined that each point in-
crease should relate to the minimal important difference
(MID) of the FT (6 points) [21].2.6. Statistical analysis and development of the
COMCOLD index
Continuous variables are presented as means with stan-
dard deviations (SDs), categorical data as frequencies and
percentages. We examined the prevalence of existing co-
morbidities and only considered those with a prevalence
O5% in the development of the index. We reported data
on the prevalence of rarer, miscellaneous comorbidities
categorized by disease group. To determine the independent
impact of comorbidities on patient-reported health status,
we used regression models to calculate associations be-
tween each comorbidity (with prevalenceO5%) or catego-
rized disease groups (including comorbidities with
prevalence 5%) and health status (FT) as outcome indi-
vidually, adjusted for FEV1 in % predicted.
To decide on inclusion of comorbidities that reflect the
combined impact on health status (FT) for the index, we
applied two selection procedures: (1) stepwise backward
selection of comorbidities by regression analysis and (2)
consistency over time by repeating the analyses for five
cohort assessment times. In detail, we conducted a multiple
linear regression model with the FT as dependent variable
and comorbidities with prevalence O5% as independent
variables with backward selection and a P  0.1 criterion
to retain variables in the model, adjusted for FEV1 in %
predicted. We performed this model with the data of the
baseline assessment and repeated it with the data of the
6, 12, 18, and 24 months follow-up assessments. We did
not adjust for age and sex because such adjustment could
mask the effect of comorbidities on health status. However,
we conducted a sensitivity analysis where we additionally
adjusted for age and sex. We conducted the final multiple
linear regression analysis on which the index is based on
the data of the baseline assessment, the most comprehen-
sive sample where no patients are lost to follow-up. For
the final regression model, we selected those comorbidities,
which were retained in the backward selection model
(adjusted for FEV1 in % predicted) at least three assess-
ment times of the five.
We developed the COMCOLD index by transforming
the final model’s regression coefficients into an index sys-
tem that reflected the underlying association of the included
comorbidities with health status (1 point per increase of the
coefficient by 0.25 MID, 1.5 points of the FT). We tested
for possible interaction between FEV1 in % predicted and
the index. To assess construct validity, we calculated Pear-
son correlation coefficients between the COMCOLD index
and the following validation measures: (1) The total
number of drugs taken regularly as another measure of
Table 1. Patient characteristics of the COPD patients enrolled in the
cohort study (n 5 408)
Characteristics Mean (SD) or n (%)a
Age 67.3 (10.0)
Sex (male, n, %) 233 (57.1)
FEV1 in % predicted 55.6 (16.6)
MRC 1.9 (1.5)
Feeling thermometer 68.3 (15.5)
Number of comorbidities 3.2 (2.2)
Number of drugs 2.9 (2.3)
GOLD stage II: 261 (64.0); III: 89 (21.8);
IV: 58 (14.2)
New GOLD stage A: 171 (41.9); B: 90 (22.1);
C: 55 (13.5); D: 92 (22.6)
Abbreviations: FT, Feeling Thermometer; GOLD, Global Initiative
for Chronic Obstructive Lung Disease; MRC, Medical Research Coun-
cil questionnaire; SD, standard deviation.
a One patient did not complete the FT.
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(2) exercise capacity assessed by sit-to-stand test [29]
(moderate negative correlations expected), (3) physical ac-
tivity assessed by self-administered Longitudinal Aging
Study Amsterdam (LASA) Physical Activity Questionnaire
[30] (moderate negative correlations expected), and (4)Fig. 1. Prevalence of specific comorbidities (prevalenceO5%) and categorie
5%) (n 5 408).disease-specific HRQL assessed by CRQ [23] [moderate
negative correlations with CRQ domains expected and cor-
relations for the more generic domains (emotional and fa-
tigue) expected to be stronger than those for the more
COPD-specific domains (dyspnea and mastery)]. All ana-
lyses were done using STATA (version 11.2, 12, and 13;
StataCorp LP, College Station, TX, USA).3. Results
3.1. Patient characteristics and comorbidities
We excluded one patient who did not complete the FT at
baseline but included all other 408 patients in the analysis.
A total of 57.1% of the patients were male, and the mean
age was 67.3 years (SD 5 10.0) (Table 1). A total of
90.7% (n 5 370) of the patients had at least one comorbid-
ity: 16.9% (n 5 69) had one, 17.4% (n 5 71) had two,
17.7% (n 5 72) had three, and 38.7% (n 5 158) had 4
comorbidities. The most prevalent comorbidities were hy-
pertension (42.2%), followed by arthrosis (29.4%), obesity
(20.3%), and symptomatic heart disease (coronary heart
disease or heart failure, 20.3%) (Fig. 1).s of comorbidities (categorized specific comorbidities with prevalence
Table 2. Individual associations of specific comorbidities (prevalence
O5%) and disease groups (categorized specific comorbidities with
prevalence 5%) with patient-reported health status (FT)
(n 5 408)
Specific comorbidities
and disease groups
Coefficientsa,b
(change in
FT score if
comorbidity
is present) 95% CI
Specific comorbidities with prevalence O5%
Hypertension 3.21 6.12, 0.3
Arthrosis 1.96 5.12, 1.20
Obesity (BMI 30) 6.36 9.91, 2.81
Symptomatic heart diseasec 4.44 8.00, 0.88
Chronic kidney disease 2.35 6.05, 1.35
Diabetes 5.50 9.46, 1.55
Depression 11.42 15.57, 7.27
Anxiety 9.29 13.69, 4.89
Cerebrovascular diseased 4.04 9.12, 1.03
Arrhythmia 1.83 3.61, 7.27
Peripheral artery disease 5.15 11.04, 0.73
Dyslipidemia 3.93 9.94, 2.08
Disease groups, containing categorized specific comorbidities with
prevalence 5%
Tumor disease group 0.95 3.24, 5.14
Gastrointestinal disease group 0.59 4.60, 5.78
Pulmonary disease group 0.87 6.09, 4.34
Infectious disease group 8.50 16.38, 0.62
Urological disease group 4.80 13.37, 3.78
Dermatological disease group 0.91 8.44, 10.26
Allergic disease group 4.19 14.00, 5.63
Ophthalmologic disease group 7.66 3.43, 18.74
Ear, nose, throat disease group 7.95 6.67, 22.57
Abbreviations: CI, confidence interval; FT, Feeling Thermometer.
a All adjusted for FEV1 in % predicted.
b The coefficients describe the change in health status in points
on the FT.
c Coronary heart disease and/or heart failure.
d Cerebrovascular accident or transient ischemic attack.
Table 4. COMCOLD index (range 0e19)
Comorbidity Points
Depression 6
Anxiety 4
Peripheral artery disease 3
Cerebrovascular diseasea 3
Symptomatic heart diseaseb 3
Abbreviation: COMCOLD, COMorbidities in Chronic Obstructive
Lung Disease.
a Cerebrovascular accident or transient ischemic attack.
b Coronary heart disease and/or heart failure.
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status
Adjusted for FEV1 in % predicted, depression, anxiety,
obesity, diabetes, symptomatic heart disease, hypertension,
and peripheral artery disease were individually associated
(regression coefficients of 3 5 at least 0.5 MID of FT;
P  0.1) with FT scores (Table 2).Table 3. Final regression model with selected specific comorbidities as
predictors and patient-reported health status (FT) as outcome
(n 5 408)a
Comorbidity Coefficients 95% CI
Depression 9.00 13.52, 4.48
Anxiety 5.53 10.25, 0.81
Peripheral artery disease 5.02 10.64, 0.60
Cerebrovascular diseaseb 4.57 9.43, 0.29
Symptomatic heart diseasec 3.81 7.23, 0.39
Abbreviation: FT, Feeling Thermometer.
a Based on baseline assessment data and adjusted for FEV1 in %
predicted.
b Cerebrovascular accident or transient ischemic attack.
c Coronary heart disease and/or heart failure.Depression, anxiety, cerebrovascular disease (cerebro-
vascular accident or transient ischemic attack), peripheral
artery disease, and symptomatic heart disease remained at
least at three of five assessment times in the multiple
backward selection regression model and, therefore, were
considered for the final regression analysis. Hypertension,
arthrosis, diabetes, and dyslipidemia were removed from
the model at all five assessments, whereas obesity, chronic
kidney disease, and arrhythmia each remained in a model
once. Table 3 shows the results of the final regression
analysis. The sensitivity analysis that also adjusted for
age and sex resulted in almost identical coefficients for
comorbidities.3.3. Development of the COMCOLD index
We generated the index that reflects the strength of asso-
ciation between each of the five comorbidities with health
status: 6 points for depression (coefficient, 9.00), 4 points
for anxiety (coefficient, 5.53), and 3 points for peripheral
artery disease (coefficient, 5.02), cerebrovascular disease
(coefficient, 4.57) and symptomatic heart disease (coeffi-
cient, 3.81). This resulted in an index ranging from 0 (no
impact of comorbidity on health status) to 19 (very large
impact of comorbidity on health status) (Table 4). We found
no interaction between FEV1 in % predicted and the index
(P 5 0.87). Correlations of the COMCOLD index with
validation measures were in the ranges we had expected
(Table 5).Table 5. Construct validity: Pearson correlation coefficient between
COMCOLD index and other measures (n 5 408)
Measures Pearson’s correlation coefficients (95% CI)
Drug count 0.36 (0.27, 0.44)
Sit-to-stand testa 0.20 (0.30, 0.10)
LAPAQ score 0.30 (0.39, 0.21)
CRQ dyspnea 0.25 (0.34, 0.16)
CRQ fatigue 0.38 (0.46, 0.30)
CRQ emotional 0.49 (0.56, 0.41)
CRQ mastery 0.35 (0.43, 0.26)
Abbreviations: CI, confidence interval; COMCOLD, COMorbidities
in Chronic Obstructive Lung Disease; CRQ, Chronic Respiratory Ques-
tionnaire; LAPAQ, LASA Physical Activity Questionnaire.
a n 5 373.
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Our study showed that depression had the largest impact
on patient-reported health status of patients with COPD,
followed by anxiety, peripheral artery disease, cerebrovas-
cular disease, and symptomatic heart disease. The COM-
COLD index reflects the impact of these five
comorbidities on health status in patients with COPD and
may be attractive for both clinicians and researchers.
Overall, our results illustrate that researchers and clini-
cians should carefully consider the outcome an index pre-
dicts. Comorbidity indices developed to predict mortality
are not designed to predict a patient-reported health
outcome where other comorbidities are likely to be rele-
vant. One apparent difference between the COMCOLD in-
dex and comorbidity indices that were developed to predict
mortality, like the Charlson index [7] or the recently pre-
sented COPD-specific COTE index [11], is the role of
mental diseases. Depression was most strongly associated
with poor health status and contributed more than any other
comorbidity to the COMCOLD index. Depression is
neither part of the Charlson index nor of the COTE index.
Interestingly, anxiety, the other psychiatric disease that
was strongly and independently associated with health sta-
tus in our study, was also found to be associated with mor-
tality in women and contributes to the COTE index [11].
The relevance of psychiatric comorbidities was also shown
in a recently presented comorbidity index that was devel-
oped based on how well diagnoses were associated with
generic HRQL in patients with any chronic condition, not
specifically in patients with COPD. Anxiety and depression
not only had the greatest association with the Short Form-
12 mental component summary score, but were also related
to the Short Form-12 physical component summary score
[31].
We further found cerebrovascular disease and peripheral
artery disease to be meaningfully associated with worse
health status. Cerebrovascular disease and peripheral artery
disease also contribute to the Charlson index but were not
related to mortality risk in the study by Divo et al. [11].
In contrast, symptomatic heart disease is both relevant for
patient-reported health status and mortality. Not surpris-
ingly, cancer diagnoses contribute most to indices predict-
ing death [7,11]. In our study, the combined category
‘‘any tumor disease’’ was not found to be associated with
patient-reported health status, and we did not assess indi-
vidual cancers due to low prevalence of specific cancers
(!5%). One possible explanation for the missing impact
could be that we excluded patients with life expectancy
with less than 12 months [18].
Previous studies assessing associations between comor-
bidities and patient-reported health outcomes in patients
with COPD usually focused on HRQL, not particularly
on health status. Consistently, prior studies have found as-
sociations between an increasing number of comorbidities
and decreasing HRQL in patients with COPD, but thecontribution of specific comorbidities was less clear
[2,16,17]. Among the five relevant comorbidities detected
in our study, depression and anxiety were previously found
to be associated with impaired HRQL in a study that as-
sessed the impact of these two disorders only [13]. Crisaful-
li et al. [32] found that heart disease significantly reduced
the beneficial effects of pulmonary rehabilitation on
perceived disease-specific HRQL in patients with COPD.
In contrast to our results, Wijnhoven et al. [17] found that
out of three interviewer-assessed chronic comorbidities
(hypertension, cardiac diseases, and musculoskeletal disor-
ders), only musculoskeletal disorders were associated with
poor generic HRQL in patients with COPD. Van Manen
et al. [15] found that COPD and comorbidity were related
to impairment in the SF-36 dimensions of physical func-
tioning, vitality, and general health. Impairment in the
SF-36 dimensions of social and emotional functioning did
not seem to be primarily related to COPD, but rather to
the presence of comorbidities. Besides, Lopez Varela
et al. [2] found in a population-based study on COPD prev-
alence that out of seven selected self-reported comorbid-
ities, diabetes was the comorbidity that most affected the
general health status of individuals with COPD in bivariate
analysis. Diabetes was also found to have an independent
impact on health status in our study; however, it lost its
impact when considered together with other comorbidities
in multiple regression analysis.
A limitation of our study is that we focused on comor-
bidities that had at least a prevalence of 5% or more in
our cohort. Although the impact of rarer comorbidities is
likely to be smaller from a population perspective, they
may still represent a substantial burden in terms of effect
on health status for individual patients. However, we
decided not to consider them because fewer cases lead to
lower precision for the estimates of associations. Another
limitation is that the COMCOLD index does not consider
that for some disease combinations, a synergistic effect
on health status may exist. However, a recently published
community-based cohort study found that effects of interac-
tion between comorbidities in elderly on several health out-
comes including self-rated health were primarily additive,
not synergistic [33]. Finally, further research is needed to
examine whether the index can be replicated in other pop-
ulations of patients with COPD.
Strength of our study is the comprehensive assessment
of the data on comorbidities based on several sources that
included patient reports, patient charts (ie, physicians re-
ports; Switzerland only) and additional tests (eg, serum
creatinine). Because we were able to verify some of the co-
morbidity data of patients with the additional tests after
publication of the baseline results [19], descriptive comor-
bidity results from our cohort have slightly changed.
Furthermore, the population from primary care settings in
two countries enabled us to assess the full spectrum of
COPD and comorbidities, which increased the chance of
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ally, with the FT, we used a well-validated and easy-to-
use instrument that assesses the patients’ generic health sta-
tus. Because a disease-specific quality of life instrument
like for example the CRQ or the St. George’s Respiratory
Questionnaire focuses on COPD-specific physical (eg,
dyspnea, fatigue) and mental impairment (eg, depression,
anxiety), it is likely to miss the impact of some
comorbidities.
In practice, the COMCOLD index can help clinicians to
identify burden from comorbidities in patients with
COPD. A high COMCOLD score reflects a substantial
level of burden for the patient. This overall impression
can be useful to discuss and prioritize treatment options
with the patient and prevent overtreatment. Overtreatment
will most likely be an issue in this older, multi-morbid pa-
tient population, for whom clinical practice guidelines
from several diseases must be integrated to propose care-
fully individualized treatment [34], if possible at all. In
addition, the COMCOLD index supports clinicians to
recognize comorbidities and treatment possibilities that
are not known to be associated with an increased risk of
death in patients with COPD but rather influence how pa-
tients are currently feeling. For example, a patient with
COPD with comorbid depression and peripheral artery dis-
ease is not at much higher risk for death according to the
Charlson index (1 point of 37 possible points) or COTE in-
dex (0 points of 19 or 25 possible points). However, the
COMCOLD index (9 points of 19 possible points) indi-
cates that this patient suffers from a decreased health sta-
tus and may benefit from effective treatment of the two
comorbidities.
In research, the COMCOLD index can be used to study
effect modification, specifically the effect comorbidities
have on treatment outcomes. Although it is currently well
known that comorbidities are highly prevalent in patients
with COPD, patients with comorbidities are often either
excluded from clinical trials or their comorbidities are
not considered for treatment effect analyses, which call
into question the generalization of such results [35]. The
COMCOLD index provides an efficient way to assess
whether or not treatment effects vary according to the
extent of multi-morbidity in previous and future COPD
treatment trials.5. Conclusion
Depression, anxiety, peripheral artery disease, cerebro-
vascular disease, and symptomatic heart disease had the
greatest impact on health status of patients with COPD.
The COMCOLD index reflects this impact and comple-
ments other comorbidity indices predicting death. The
COMCOLD index may help clinicians to focus their atten-
tion on the most important comorbidities from a patients’
perspective, and researchers may use the index to assess
the impact of comorbidities in treatment effects.Acknowledgments
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